327 results
8-K
INFIQ
Infinity Pharmaceuticals, Inc.
1 Sep 23
Cost Associated with Exit or Disposal Activities
4:06pm
to severance payments, employee benefits and stock-based compensation. The estimates of expenses and cash costs that the Company expects to incur … Executive Severance Benefits Plan (the “Severance Plan”), Ms. Perkins is entitled to receive a severance payment representing twelve months of base
8-K
INFIQ
Infinity Pharmaceuticals, Inc.
25 Jul 23
Infinity Pharmaceuticals Announces Value Preservation and Maximization Plan
4:30pm
to severance payments and employee benefits. The estimates of expenses and cash costs that the Company expects to incur, and the timing thereof
DEFA14A
INFIQ
Infinity Pharmaceuticals, Inc.
10 Jul 23
Additional proxy soliciting materials
8:30am
the proposed merger considering the various closing conditions; the expected benefits of the proposed merger, including estimations of anticipated cost savings … the consummation of the proposed merger or result in the imposition of conditions that could reduce the anticipated benefits from the proposed merger or cause
DEFA14A
INFIQ
Infinity Pharmaceuticals, Inc.
5 Jul 23
Additional proxy soliciting materials
8:30am
”).
ISS’s evaluation and endorsement of the merger with MEI underscores the key potential benefits of the transaction for Infinity stockholders as part … considering the various closing conditions; the expected benefits of the proposed merger, including estimations of anticipated cost savings and cash
425
7jtq3l28 ic7oizt
3 Jul 23
Business combination disclosure
4:57pm
8-K
a138695
3 Jul 23
Other Events
4:55pm
DEFA14A
6gv7lzvao bw7
20 Jun 23
Additional proxy soliciting materials
8:30am
425
0zo8vfj 3ve
20 Jun 23
Business combination disclosure
8:02am
425
EX-99.1
cc37 u1gs
20 Jun 23
Business combination disclosure
8:02am
425
EX-99.2
7sj1i5
20 Jun 23
Business combination disclosure
8:02am
8-K
ny0iai cn
20 Jun 23
Overview and Update on Pending Merger to Advance Three Promising Clinical
8:00am
8-K
EX-99.2
yn3crf4
20 Jun 23
Overview and Update on Pending Merger to Advance Three Promising Clinical
8:00am
8-K
EX-99.1
d0sqg
20 Jun 23
Overview and Update on Pending Merger to Advance Three Promising Clinical
8:00am
DEFA14A
gw86pfpzxn6jvk
16 Jun 23
Additional proxy soliciting materials
12:33pm
DEFA14A
qam muqvtbjtac
6 Jun 23
Additional proxy soliciting materials
4:43pm
DEFM14A
l8lwso4 btepo0
6 Jun 23
Proxy related to merger
4:31pm